All of Us study identifies thousands of new genetic drug variants
Researchers using data from the National Institute of Health's All of Us program published findings on Wednesday in Science Translational Medicine regarding new genetic variants affecting drug responses.
Study finds thousands of new variants
The analysis examined nearly 100,000 Americans to identify thousands of new variants within a specific set of genes. Every participant in the study carried at least one variant in the 16 pharmacogenes the researchers studied. A quarter of the study subjects used drugs whose effects might change due to these recently discovered genetic variations. Such variants affect the way individuals process medications including selective serotonin reuptake inhibitors, statins, chemotherapy, and Plavix, a blood thinner.
Diverse data improves clinical outcomes
The All of Us Research Program aims to collect genetic data from 1 million Americans from diverse backgrounds. Such variety allowed researchers to spot variants absent from earlier studies that relied on different genomic repositories such as the U.K. Biobank. Congress provides annual funding alongside support from the 21st Century Cures Act, which was enacted in 2016 for this program. Funding for the initiative will dry up in the 2027 fiscal year under current budget projections.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.